Supplemental material
Open access
10,077
Views
9
CrossRef citations to date
0
Altmetric
Review
Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches
Tushar Jaina Adimab LLC, Palo Alto, CA, USACorrespondence[email protected]
https://orcid.org/0000-0002-9261-803XView further author information
Todd Bolandb Computational Biology, Adimab LLC, Lebanon, NH, USAView further author information
& Maximiliano Vásqueza Adimab LLC, Palo Alto, CA, USAView further author information
Article: 2200540
|
Received 13 Feb 2023, Accepted 04 Apr 2023, Published online: 18 Apr 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.